AbbVie sees hit to Humira sales from European competition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil hits one-week low as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- Six Flags to move headquarters from Charlotte to Arlington, Texas
Abbvie (ABBV) PT Lowered to $71 at BMO Capital
November 5, 2018 8:47 AM ESTBMO Capital analyst Alex Arfaei lowered the price target on Abbvie (NYSE: ABBV) to $71.00 (from $78.00) while maintaining a Underperform rating.
The analyst commented, "3Q18 was fine, but not great; particularly the Imbruvica beat. The market is ignoring management's long-term guidance, and signals of... More
